Published in Transplant Rev (Orlando) on April 10, 2009
Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res (2011) 1.28
Antibodies in transplantation. Discov Med (2010) 1.18
The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection. Trends Mol Med (2015) 0.90
An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA. Am J Transplant (2015) 0.89
Genotypic diversity of complement component C4 does not predict kidney transplant outcome. J Am Soc Nephrol (2010) 0.86
Pathogenesis and significance of glomerular C4d deposition in lupus nephritis: activation of classical and lectin pathways. Int J Clin Exp Pathol (2013) 0.85
Characterization of transfusion-elicited acute antibody-mediated rejection in a rat model of kidney transplantation. Am J Transplant (2014) 0.80
Antibody-mediated rejection: an evolving entity in heart transplantation. J Transplant (2012) 0.79
Late and chronic antibody-mediated rejection: main barrier to long term graft survival. Clin Dev Immunol (2013) 0.79
Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient. Antimicrob Agents Chemother (2014) 0.79
The importance of C4d in biopsies of kidney transplant recipients. Clin Dev Immunol (2013) 0.79
Tolerogenic Dendritic Cells on Transplantation: Immunotherapy Based on Second Signal Blockage. J Immunol Res (2015) 0.79
Antibody therapy can enhance AngiotensinII-induced myocardial fibrosis. Fibrogenesis Tissue Repair (2014) 0.77
Complement activation in astrocytomas: deposition of C4d and patient outcome. BMC Cancer (2012) 0.76
Unraveling the Role of Allo-Antibodies and Transplant Injury. Front Immunol (2016) 0.75
Early decreased plasma levels of factor B and C5a are important biomarkers in children with Kawasaki disease. Pediatr Res (2015) 0.75
Spleen tyrosine kinase contributes to acute renal allograft rejection in the rat. Int J Exp Pathol (2014) 0.75
Autoantibody formation in human and rat studies of chronic rejection and primary graft dysfunction. Semin Immunol (2011) 0.75
Detection of T and B cells specific complement-fixing alloantibodies using flow cytometry: A diagnostic approach for a resource limited laboratory. Asian J Transfus Sci (2017) 0.75
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant (2005) 5.87
Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage. J Clin Invest (1978) 5.80
Significance of the positive crossmatch test in kidney transplantation. N Engl J Med (1969) 5.50
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant (2003) 4.54
C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science (1996) 4.35
Neutrophils are essential for early anti-Listeria defense in the liver, but not in the spleen or peritoneal cavity, as revealed by a granulocyte-depleting monoclonal antibody. J Exp Med (1994) 4.16
Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant (2007) 3.90
RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation (2001) 3.86
Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med (2002) 3.39
Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med (1995) 3.38
Neutrophils are involved in acute, nonspecific resistance to Listeria monocytogenes in mice. Infect Immun (1993) 3.38
The chemotactic receptor for human C5a anaphylatoxin. Nature (1991) 3.15
Polymorphonuclear leukocyte chemotactic activity in rabbit serum and Guinea pig serum treated with immune complexes: evidence for c5a as the major chemotactic factor. Infect Immun (1970) 3.01
CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell (2006) 2.89
C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant (2006) 2.81
Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood (2003) 2.73
Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci U S A (1996) 2.71
C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol (1997) 2.69
Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature (2006) 2.69
Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood (2002) 2.62
Decay-accelerating factor modulates induction of T cell immunity. J Exp Med (2005) 2.34
Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem (1989) 2.20
The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol (1992) 2.17
C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature (2007) 2.06
Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J Immunol (1974) 2.02
Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol (2002) 2.02
Antibody-mediated organ-allograft rejection. Nat Rev Immunol (2005) 1.99
Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature (1985) 1.98
C5a-induced expression of P-selectin in endothelial cells. J Clin Invest (1994) 1.93
C5L2, a nonsignaling C5A binding protein. Biochemistry (2003) 1.90
Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem (1988) 1.88
Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J Exp Med (1991) 1.88
Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol (2002) 1.84
Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int (1993) 1.80
Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin. Blood (2005) 1.78
Platelet activation leads to activation and propagation of the complement system. J Exp Med (2005) 1.76
Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol (2001) 1.72
The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol (1991) 1.68
The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. J Immunol (2001) 1.59
Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production. J Immunol (2007) 1.59
Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. J Immunol (1996) 1.58
Quantification of mouse macrophage chemotaxis in vitro: role of C5 for the production of chemotactic activity. Infect Immun (1975) 1.57
Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J Immunol (2006) 1.57
Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant (2003) 1.54
Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol (2002) 1.53
Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol (2002) 1.52
VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest (2006) 1.51
Characterization of a receptor for C5a anaphylatoxin on human eosinophils. J Biol Chem (1989) 1.49
Human mannose-binding protein activates the alternative complement pathway and enhances serum bactericidal activity on a mannose-rich isolate of Salmonella. J Clin Invest (1989) 1.47
Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol (1991) 1.42
Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation (2000) 1.42
Complement C4d in graft capillaries -- the missing link in the recognition of humoral alloreactivity. Am J Transplant (2003) 1.41
Inhibition of polymorphonuclear leukocyte-mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection. Circulation (2005) 1.39
Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J (2003) 1.38
Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant (2005) 1.37
P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood (2003) 1.34
C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol (2004) 1.34
Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol (2002) 1.33
Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo. Immunobiology (2006) 1.30
Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg. J Immunol (1985) 1.30
The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells. Am J Pathol (1996) 1.29
Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med (1995) 1.26
Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2+ and association with cellular Ca2+. J Immunol (1986) 1.25
Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation (2001) 1.24
Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant (2005) 1.24
The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation (1990) 1.24
Human platelet activation by C3a and C3a des-arg. J Exp Med (1983) 1.22
The allogeneic T and B cell response is strongly dependent on complement components C3 and C4. Transplantation (2001) 1.20
Solution structure of human and mouse immunoglobulin M by synchrotron X-ray scattering and molecular graphics modelling. A possible mechanism for complement activation. J Mol Biol (1991) 1.18
In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ Res (2008) 1.17
The differing roles of the classical and mannose-binding lectin complement pathways in the events following skeletal muscle ischemia-reperfusion. J Immunol (2006) 1.17
Expression and function of the C5a receptor in rat alveolar epithelial cells. J Immunol (2002) 1.14
Membrane attack complex contributes to destruction of vascular integrity in acute lung allograft rejection. J Immunol (2002) 1.13
Synergistic deposition of C4d by complement-activating and non-activating antibodies in cardiac transplants. Am J Transplant (2007) 1.13
Transient perturbation of endothelial integrity induced by natural antibodies and complement. J Exp Med (1995) 1.11
Altered neutrophil trafficking during sepsis. J Immunol (2002) 1.11
The cellular lesion of humoral rejection: predominant recruitment of monocytes to peritubular and glomerular capillaries. Am J Transplant (2007) 1.10
Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. Curr Opin Cardiol (2004) 1.09
Antibody-mediated rejection in renal allografts: lessons from pathology. Clin J Am Soc Nephrol (2006) 1.09
The involvement of FcR mechanisms in antibody-mediated rejection. Transplantation (2007) 1.08
Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol (2007) 1.07
Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA (2004) 1.07
Poly's plea: membership to the club of APCs. Trends Immunol (2003) 1.06
Acute renal allograft rejections with major interstitial oedema and plasma cell-rich infiltrates: high gamma-interferon expression and poor clinical outcome. Nephrol Dial Transplant (2004) 1.03
Secretory vesicles are the intracellular reservoir of complement receptor 1 in human neutrophils. J Immunol (1994) 1.03
C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: epithelial and endothelial priming is required for C3a-induced eosinophil adhesion. Immunopharmacology (2000) 1.03
Complementary adhesion molecules promote neutrophil-Kupffer cell interaction and the elimination of bacteria taken up by the liver. J Immunol (2002) 1.02
C4d staining of pulmonary allograft biopsies: an immunoperoxidase study. J Heart Lung Transplant (2005) 1.01
C4d deposition in lung allografts is associated with circulating anti-HLA alloantibody. Transpl Immunol (2005) 1.00
Cleavage of the third component of complement (C3) by mannose-binding protein-associated serine protease (MASP) with subsequent complement activation. Immunobiology (1995) 1.00
Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine. Transplantation (2005) 0.95
Evidence that humoral allograft rejection in lung transplant patients is not histocompatibility antigen-related. Am J Transplant (2003) 0.95
Cytosolic calcium and protein kinase C reduce complement-mediated glomerular epithelial injury. Kidney Int (1990) 0.95
Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res (2002) 2.07
Regulation of platelet granule exocytosis by S-nitrosylation. Proc Natl Acad Sci U S A (2005) 1.52
Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A (2007) 1.39
Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain (2010) 1.38
Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol (2008) 1.33
Update on cardiac transplantation pathology. Arch Pathol Lab Med (2007) 1.33
Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant (2005) 1.24
In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ Res (2008) 1.17
Non-complement- and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am J Transplant (2004) 1.14
HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res (2005) 1.14
Cutting edge: Generation of colitogenic Th17 CD4 T cells is enhanced by IL-17+ γδ T cells. J Immunol (2011) 1.13
Membrane attack complex contributes to destruction of vascular integrity in acute lung allograft rejection. J Immunol (2002) 1.13
Antibody and complement in transplant vasculopathy. Circ Res (2007) 1.12
Inhibition of N-ethylmaleimide-sensitive factor protects against myocardial ischemia/reperfusion injury. Circ Res (2007) 1.08
The involvement of FcR mechanisms in antibody-mediated rejection. Transplantation (2007) 1.08
New concepts of complement in allorecognition and graft rejection. Cell Immunol (2007) 1.02
Signal transducer and activator of transcription 3alpha and specificity protein 1 interact to upregulate intercellular adhesion molecule-1 in ischemic-reperfused myocardium and vascular endothelium. Arterioscler Thromb Vasc Biol (2005) 0.99
Decreased capacity of immune cells to cause tissue injury mediates kidney ischemic preconditioning. J Immunol (2006) 0.96
Absence of mannose-binding lectin prevents hyperglycemic cardiovascular complications. Am J Pathol (2011) 0.96
B cells and plasma cells in coronaries of chronically rejected cardiac transplants. Transplantation (2010) 0.94
Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation (2007) 0.92
Platelets contribute to allograft rejection through glutamate receptor signaling. J Immunol (2010) 0.91
Platelets present antigen in the context of MHC class I. J Immunol (2012) 0.91
Terminal complement components mediate release of von Willebrand factor and adhesion of platelets in arteries of allografts. Transplantation (2005) 0.90
The production of red blood cell alloantibodies in mice transfused with blood from transgenic Fyb-expressing mice. Transfusion (2006) 0.89
White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion (2010) 0.88
An extraribosomal function of ribosomal protein L13a in macrophages resolves inflammation. J Immunol (2013) 0.88
Cutting edge: IFN-γR signaling in non-T cell targets regulates T cell-mediated intestinal inflammation through multiple mechanisms. J Immunol (2014) 0.88
Antibody and complement mediated injury in transplants following sensitization by allogeneic blood transfusion. Transplantation (2006) 0.85
A TLR5 agonist inhibits acute renal ischemic failure. J Immunol (2011) 0.84
Alloantibody induced platelet responses in transplants: potent mediators in small packages. Hum Immunol (2012) 0.83
Hapten application to the skin induces an inflammatory program directing hapten-primed effector CD8 T cell interaction with hapten-presenting endothelial cells. J Immunol (2011) 0.83
Ribosomal protein L13a deficiency in macrophages promotes atherosclerosis by limiting translation control-dependent retardation of inflammation. Arterioscler Thromb Vasc Biol (2014) 0.82
Anti-human leukocyte antigen antibodies, vascular C4d deposition and increased soluble c4d in broncho-alveolar lavage of lung allografts. Transplantation (2008) 0.81
Stat3β mitigates development of atherosclerosis in apolipoprotein E-deficient mice. J Mol Med (Berl) (2013) 0.80
Cardiac allograft vasculopathy: do adipocytes bridge alloimmune and metabolic risk factors? Curr Opin Organ Transplant (2010) 0.80
Peroxynitrite inhibition of Coxsackievirus infection by prevention of viral RNA entry. Proc Natl Acad Sci U S A (2004) 0.79
Antibody, complement and accommodation in ABO-incompatible transplants. Curr Opin Immunol (2004) 0.79
CXCL12 induction of inducible nitric oxide synthase in human CD8 T cells. J Heart Lung Transplant (2008) 0.78
Absence of FcγRIII results in increased proinflammatory response in FcγRIII-KO cardiac recipients. Transplantation (2013) 0.78
C4d deposition and cellular infiltrates as markers of acute rejection in rat models of orthotopic lung transplantation. Transplantation (2008) 0.78
A platelet-inspired paradigm for nanomedicine targeted to multiple diseases. Nanomedicine (Lond) (2013) 0.78
Lymphatic injury and regeneration in cardiac allografts. Transplantation (2010) 0.78
High renal ischemia temperature increases neutrophil chemoattractant production and tissue injury during reperfusion without an identifiable role for CD4 T cells in the injury. Transpl Immunol (2009) 0.76
Immunological challenges of cardiac transplantation: the need for better animal models to answer current clinical questions. J Clin Immunol (2009) 0.76
Potential Roles for C1 Inhibitor in Transplantation. Transplantation (2016) 0.76
Extensive cardiac allograft vasculitis and concurrent fat necrosis 6 years after orthotopic heart transplantation. J Heart Lung Transplant (2007) 0.76
Impact of MHC class II incompatibility on localization of mononuclear cell infiltrates to the bronchiolar compartment of orthotopic lung allografts. Am J Transplant (2005) 0.75
Clearance of complement by human vascular endothelial cells: effects of hypoxia/reoxygenation and IL-1beta activation. Transpl Int (2005) 0.75